Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
25,001 - 50,000 - Monthly Reach
Unique listeners across all episodes (30 days)
25,001 - 75,000 - Active Followers
Loyal subscribers who consistently listen
15,001 - 40,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHost
Recent guests
Recent episodes
From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D.
May 4, 2026
55m 56s
Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
Apr 27, 2026
47m 37s
The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw
Apr 20, 2026
46m 53s
Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.
Apr 13, 2026
58m 33s
Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor
Apr 6, 2026
40m 26s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 5/4/26 |  From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D. | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brett Monia, Ph.D., CEO at Ionis Pharmaceuticals, talks about how antisense oligonucleotides (ASO) graduated from a late-1980s lab concept to real RNA-targeting medicines, and why Ionis stuck with a difficult modality despite multiple setbacks. Brett describes the company's shift from a partner-first model to building a wholly-owned pipeline, commercial function, and an expanded manufact... | 55m 56s | ||||||
| 4/27/26 | Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary✨ | CEO strategyneuroreparative peptide+3 | Adam Rogers, M.D.Rich Macary | NVG-291NervGen+2 | — | NervGenNVG-291+5 | — | 47m 37s | |
| 4/20/26 | The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw✨ | FDA decision-makingclinical trial strategy+3 | Allan Shaw | FDA | — | FDAbiotech+5 | — | 46m 53s | |
| 4/13/26 | Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.✨ | biosimilarsFDA regulations+3 | Sarfaraz Niazi, Ph.D. | FDABiologics Price Competition and Innovations Act | — | biosimilarsFDA+5 | — | 58m 33s | |
| 4/6/26 | Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor✨ | radiotherapeuticsneuroendocrine tumors+3 | Thijs Spoor | Pb 212radiopharmaceuticals+1 | — | radiotherapeuticsneuroendocrine tumors+3 | — | 40m 26s | |
| 3/30/26 | Investing In Early-Stage Oncology With Yosemite's Dan McHugh✨ | oncologyinvestment+3 | Dan McHugh | Yosemite | — | oncologyinvestment+5 | — | 55m 41s | |
| 3/23/26 | Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash✨ | CAR T therapybiotech commercialization+3 | Alan Bash | CarvyktiLegend Biotech+3 | — | CAR T therapyCarvykti+5 | — | 50m 57s | |
| 3/16/26 | Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.✨ | radiotherapeuticsCNS cancers+4 | Marc Hedrick, M.D. | ReyobiqPlus Therapeutics+2 | — | radiotherapeuticsCNS cancers+5 | — | 54m 00s | |
| 3/9/26 | Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.✨ | cancer drug developmentcapital efficiency+3 | Rahul Aras, Ph.D. | Iterion Therapeutics | — | cancerdrug development+4 | — | 48m 30s | |
| 3/2/26 | Making Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.✨ | biologicsoral drugs+3 | Thomas von Erlach, Ph.D.Thomas von Erlach | VivtexNovo Nordisk | MIT | biologicsoral availability+7 | — | 53m 57s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 2/23/26 | An Anthropological Lens On Leadership In Life Sciences With Bunka's Monika Sumra, Ph.D.✨ | leadershipculture+3 | Monika Sumra, Ph.D. | Bunka, Inc. | — | leadershipculture+5 | — | 58m 19s | |
| 2/16/26 | Company Turnarounds And AI For Infectious Diseases With Seek Labs' Jared Bauer | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases. Jared explains the technology convergence that was needed to build Seek Labs' AI diagnostic and CRISPR-based therapeutics platform, an African Swine Fever proof-of-concept ... | 56m 56s | ||||||
| 2/9/26 | Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies. Perettie talks about scaling cell therapies in the community setting, global manufacturing strategy, preparing for the launch of late-stage development programs in lymphoma and multiple myeloma, and working with partners like Ar... | 42m 36s | ||||||
| 2/2/26 | BoB@JPM: Brian Hilberdink, Boehringer Ingelheim | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, and following his departure from LEO Pharma (see episode 164). Brian talks about new opportunities in obesity, the benefits of private ownership in funding early science, Boehringer's deal strategy, using AI to improve commercialization efforts, and ... | 44m 35s | ||||||
| 1/26/26 | BoB@JPM: Ron Cooper, enGene | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of ke... | 55m 57s | ||||||
| 1/19/26 | BoB@JPM: Marc Salzberg, M.D., Airway Therapeutics | We love to hear from our listeners. Send us a message. The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 - 15) and this week we sit down with Marc Salzberg, M.D., CEO, CMO, and Board Chair at Airway Therapeutics, a company developing a recombinant version of human surfactant protein D for several respiratory, inflammatory, and infectious diseases including bronchopulmonary dysplasia (BPD), which is currently in Phase 2b/3 trials. Brian ta... | 36m 08s | ||||||
| 1/12/26 | A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&J, Merck, Daiichi Sankyo, and GSK. Ken talks about Zymeworks' shift to a royalty model for development funding and value creation, lessons learn... | 58m 44s | ||||||
| 1/5/26 | Life Science Connect Editors' Roundtable: Wrapping Up 2025 And Looking Ahead | We love to hear from our listeners. Send us a message. This week's special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and reporting that mattered most in 2025, and what each editor has planned for 2026. From the RNA, cell, and gene therapy space to small molecule manufacturing, bioprocessing, drug discovery, and outsourcing, the editors weigh in on key industry tre... | 1h 21m 12s | ||||||
| 12/29/25 | Building Cell Therapy Companies With Kenai Therapeutics' Nick Manusos | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Nick Manusos, CEO at Kenai Therapeutics, talks about his experiences building cell therapy spinouts from FujiFilm Cellular Dynamics, learning from big pharma decision-making processes, and dosing the first patient with Kenai's allogeneic neuron replacement cell therapy for Parkinson's disease. Nick also talks about funding an early-stage cell therapy company and forging key manufacturing... | 46m 39s | ||||||
| 12/22/25 | Modernizing Clinical Trial Operations With Merck's Jennifer Sheller | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jennifer Sheller, SVP and Head of Global Clinical Trial Operations at Merck talks about simplifying trial protocols and what she likes about Merck's hybrid functional service provider model for conducting trials in over 60 countries. Jennifer shares her experiences integrating Merck's acquisitions without breaking studies or losing people, using new technology to improve trial operations... | 55m 39s | ||||||
| 12/15/25 | Transforming Chronic Kidney Disease With ProKidney's Bruce Culleton, M.D. | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Bruce Culleton, M.D., CEO at ProKidney, talks about moving from academic research to industry and the role a key mentor played in his career path. Bruce discusses his experiences as a first-time CEO at ProKidney, a late-stage autologous cell therapy biotech focused on pioneering new treatments for chronic kidney disease (CKD), the benefits of FDA's Regenerative Medicine Advanced Therapy ... | 55m 36s | ||||||
| 12/8/25 | Engineering B Cells With Immusoft's Sean Ainsworth | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Sean Ainsworth, CEO and Chairman at Immusoft, talks about transitioning from the research bench to entrepreneurship, his M&A experiences as a biotech founder, and why engineered B cell therapies offer a better, more patient-friendly administration for lysosomal storage diseases currently treated with enzyme replacement therapies. Sean also discusses FDA pathways, incentives, and agen... | 53m 51s | ||||||
| 12/1/25 | Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt | We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer. Dan describes his fast-fail approach to early product testing and development, using basket trials to evaluate chemotherapy combinations, and choosing pancreatic cancer as a lead program. He also talks about surviving an IPO during a brutal funding cycl... | 51m 25s | ||||||
| 11/24/25 | Biotech Collaboration Strategy With IGI's Cyril Konto, M.D. | We love to hear from our listeners. Send us a message. On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million upfront licensing deal with AbbVie, the impact of China's rising biotech sector, and the keys to successful collaboration. Cyril also discusses IGI's focus on developing innovative therapies for em... | 58m 41s | ||||||
| 11/17/25 | Biotech Funding And IPO Temperature Check With Create Medicine's Allan Shaw | We love to hear from our listeners. Send us a message. Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market. We discuss the implications of recent blockbuster acquisitions, strategies for managing the current funding environment for biotech, what to look for in the IPO market in the coming months, alternative financing opportunities, and what besides low... | 57m 01s | ||||||
Showing 25 of 305
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
9 placements across 9 markets.
Chart Positions
9 placements across 9 markets.